Kernel
Kernel, founded in 2016, developed Kernel Flow, a multimodal neuroimaging headset that combines high-resolution hemodynamics and EEG, and has launched Kernel Flow2, offering robust, fMRI-like functional neuroimaging.
Company History
Kernel was founded in 2016, emerging with a clear focus on advancing neuroimaging technology. Since its inception, Kernel has developed hardware products that integrate high-resolution hemodynamics and EEG, exemplified by the Kernel Flow headset. The company continues to push the boundaries of functional neuroimaging through continuous product innovation and validation in peer-reviewed publications.
Products
Kernel’s flagship product, Kernel Flow, is a premium multimodal neuroimaging headset that combines high-resolution hemodynamics and EEG. The device is portable and can be set up in under three minutes. Building on the success of Kernel Flow, the company has released Kernel Flow2, a more advanced version providing robust, fMRI-like functional neuroimaging. Kernel Flow devices have been validated through multiple peer-reviewed studies, highlighting their capability to measure biomarkers related to ketamine effects, alcohol intoxication, and psychedelic doses.
Neuroimaging Platform
Kernel's neuroimaging platform is designed to harness the power of advanced AI and ML tools to produce actionable biomarkers. This platform is data-rich and user-friendly, building on decades of functional neuroimaging advancements. It aims to improve patient outcomes, accelerate treatment development, and reduce healthcare costs through its efficient and robust design. The platform is particularly useful for translational research to identify signatures that indicate new treatments effectively engaging the brain.
Clinical and Translational Research
Kernel is actively involved in several clinical and biomarker studies. The company is enrolling participants at clinics across the West Coast to measure the effects of various depression treatments. Additionally, Kernel is recruiting healthy controls and MCI (Mild Cognitive Impairment) patients for a study on aging adults over the age of 55. The research involves measuring biomarkers to distinguish cognitive impairment levels due to alcohol intoxication and the acute effects of subanesthetic ketamine on the brain.